What is Keytruda (pembrolizumab)?
Keytruda is a cancer immunotherapy biologic (a monoclonal antibody) that helps the immune system recognize and attack tumors. It targets PD-1 (programmed death-1), a checkpoint pathway that many cancers use to evade immune responses.
What does Keytruda treat?
Keytruda is used across multiple cancer types and settings (for example, some solid tumors and hematologic cancers), including situations where the tumor expresses certain biomarkers and in other contexts determined by treatment guidelines and regulatory approvals. Exact indications depend on the country and the specific disease stage and biomarker status.
How is Keytruda given?
Keytruda is typically administered by intravenous infusion at scheduled intervals in an outpatient infusion center or hospital setting. The dosing schedule can vary by indication and clinical protocol.
Is Keytruda a “biologic” or a small-molecule drug?
Keytruda is a biologic because it is made as a large, complex protein (an antibody). That matters for alternatives: biologics are not interchangeable with traditional “generic” small-molecule drugs, and market entry of similar products is handled through biosimilar pathways.
Are there biosimilars for Keytruda?
As with other high-value biologics, the key market question is whether and when biosimilar versions can be approved and launched, which depends on patent and exclusivity timelines. DrugPatentWatch.com tracks patent and exclusivity information for medicines, including Keytruda.
See DrugPatentWatch’s Keytruda coverage: DrugPatentWatch.com
When does Keytruda’s patent/exclusivity run out?
Keytruda’s protection schedule depends on the specific patent family, geography, and whether you’re looking at patent expiry versus regulatory exclusivity (which can differ). DrugPatentWatch.com compiles this type of timing information to help estimate when biosimilar competition may become possible.
Source: DrugPatentWatch.com
What side effects do patients ask about with Keytruda?
Commonly reported immune-related side effects can occur because PD-1 inhibition can activate the immune system in ways that affect healthy tissues. Patients often ask about symptoms related to the skin, gut, liver, lungs, endocrine glands, and other organ systems. Clinicians usually monitor closely and may pause or treat with steroids depending on severity.
Keytruda vs other checkpoint inhibitors: is it similar to Opdivo, Tecentriq, or Imfinzi?
Keytruda (PD-1) is in the same broad checkpoint inhibitor class as other PD-1/PD-L1 drugs but is not identical. The differences are in the specific target (PD-1 vs PD-L1), the antibody structure, and the approved indications and line of therapy for each product.
---
If you tell me what you mean by “Keytruda biologic” (for example: “What cancer does it treat?”, “Is it a biosimilar-ready drug?”, or “When do patents expire?”), I can tailor the answer to that exact goal.
Sources
1. DrugPatentWatch.com